Healthcare Private Equity News: 2026 Sector Trends

Last updated May 2026 · covers deals and regulatory developments through May 2026.

Healthcare private equity reached a record $191 billion in global deal value in 2025, according to Bain & Company, rebounding sharply from two quieter years. From MedTech consolidation across Europe to FTC rollup investigations in the United States, the volume of healthcare private equity news has accelerated heading into 2026.

Key takeaways

• Global healthcare PE deal value hit a record $191 billion in 2025, the highest annual total on record
• Healthcare IT deal value doubled to around $32 billion; provider services deals rose 57%
• The FTC formed a dedicated Healthcare Task Force in March 2026
• California's AB 1415 and SB 351 took effect January 1, 2026, expanding state oversight of PE transactions
• Behavioral health is the top priority sub-sector, with deal activity up 47% year-on-year
• European specialist platforms including ARCHIMED and Keensight Capital are driving MedTech and HealthTech consolidation

Latest Healthcare Private Equity Deals

The table below tracks notable healthcare PE transactions. Exit buyer names are available to GP Intel Pro subscribers.

This table is updated periodically as new transactions are confirmed. European deal data is sourced from the GP Intel database; global figures are drawn from Bain & Company and the PE Stakeholder Project.

FTC Enforcement and Antitrust Pressure on Healthcare PE

Regulatory scrutiny of healthcare private equity has intensified significantly since 2023. The central concern for the FTC and DOJ is the rollup acquisition strategy: a PE-backed platform that systematically acquires competitors in a local or regional market, reducing competition and enabling price increases.

The most prominent recent case involved Welsh Carson and its portfolio company United Anesthesia Partners (USAP). In January 2025, the FTC announced a settlement requiring Welsh Carson to restrict its involvement with USAP and to provide advance notice of future acquisitions in hospital-based physician practices. A Texas district court had dismissed the FTC's original claims in 2024, but the Colorado Attorney General separately secured a resolution with USAP over conduct in that state.

In March 2026, FTC Chair Andrew Ferguson directed the formation of a dedicated Healthcare Task Force, with a mandate to coordinate enforcement and advocacy across healthcare markets. The Task Force represents a shift toward a standing enforcement posture rather than case-by-case investigation.

Enforcement outcomes have been uneven. A federal judge also declined to block GTCR's acquisition of Surmodics in 2025. Still, the formation of a permanent Healthcare Task Force signals a long-term regulatory posture. For PE firms active in US physician services or laboratory rollups, the practical implication is closer HSR scrutiny and a higher compliance burden at close.

California's Healthcare Private Equity Laws: What Changed in 2026

California moved further than any other US state to regulate PE involvement in healthcare. The original bill, AB 3129, was vetoed by Governor Newsom in 2024 after intense lobbying from the industry. In its place, two bills were signed into law and took effect January 1, 2026.

AB 1415 requires the Office of Health Care Affordability (OHCA) to review transactions involving private equity groups and hedge funds that were previously outside its jurisdiction. It also empowers OHCA to prescribe reporting requirements on healthcare costs, quality, equity, and workforce stability.

SB 351 extends California's corporate practice of medicine restrictions to any arrangement in which a PE group or hedge fund is involved with a physician or dental group. PE sponsors must ensure clinical operations remain independent from investment management decisions.

The practical effect is that any significant PE-backed acquisition of a California healthcare provider now requires an additional OHCA review layer alongside standard HSR filings. Healthcare transaction lawyers expect other states to follow: New York and Washington have observed California's legislative approach closely, and similar bills have been introduced.

European Healthcare PE: The Specialist Platforms

In Europe, regulatory pressure on healthcare private equity has been less acute than in the United States, and the market is structured differently. The dominant players are specialist platforms covering the full healthcare value chain rather than physician-services rollup acquirers.

ARCHIMED, founded in 2014 and managing €9.0 billion, is the only major European private equity platform with an exclusive focus on healthcare. It covers MedTech, pharmaceutical services, HealthTech, and biotech, with 36 active portfolio companies and 15 completed exits across six funds. In 2025 alone, ARCHIMED completed exits from Citieffe, DIESSE, and CARSO across the MedTech sub-sector, followed by the Ametris / ActiGraph HealthTech exit in 2026. Its approach targets companies with defensible positions in regulated healthcare niches, typically with equity tickets between €50 million and €300 million.

Keensight Capital, managing €8.0 billion, applies a growth equity lens to profitable technology and healthcare companies across Europe. Its healthcare focus sits within HealthTech and medical software, where software or data infrastructure is the core value driver rather than clinical services. Keensight completed healthcare exits from GEODESIAL group and Menix in 2024, and counts 34 active portfolio companies across three funds.

Andera Partners runs a dedicated Life Sciences franchise within its broader multi-strategy platform. Andera Life Sciences backs early-to-mid-stage European drug developers in biotech venture and growth. Between 2025 and 2026, Andera completed five Life Sciences exits including AgoMab, Avalyn Pharma, and Tubulis.

Larger generalist firms also carry significant healthcare exposure. Astorg lists healthcare alongside B2B services and technology as a core vertical at its €23 billion platform, with 44 exits across ten funds and the Clario exit completed in 2026. PAI Partners, with €33 billion under management, has healthcare as one of its five core sectors and exited Amplitude Surgical in 2025.

The healthcare sector page on GP Intel lists all tracked GPs with material healthcare exposure, filterable by strategy and geography.

Where Healthcare PE Activity Is Concentrated

The distribution of healthcare private equity deal activity across sub-sectors has shifted measurably since 2023.

Healthcare IT and digital health was the standout performer in 2025. Deal value in this sub-sector doubled year-on-year to approximately $32 billion, driven by AI-enabled revenue cycle management, clinical decision support, and interoperability platforms. The creation of Smarter Technologies in May 2025, combining Access Healthcare, SmarterDx, and Thoughtful.ai into an AI-powered revenue cycle platform, illustrates the pattern: PE capital backing infrastructure that reduces manual overhead for hospital systems.

Provider services saw a 57% increase in disclosed deal value in 2025. Sponsor-to-sponsor transactions dominated, with more than 150 deals representing over $120 billion in estimated value as GPs recycled assets built up by earlier vintage funds.

Behavioral health is the sub-sector drawing the most consistent forward-looking attention. A Berkeley Research Group survey in 2025 found that over 90% of PE executives in healthcare identified behavioral health as a continuing or growing investment focus. Deal activity rose 47% year-on-year through Q3 2025. Investor attention is concentrated on mental health platforms, autism services, and intellectual and developmental disability (IDD) services, where reimbursement risk is lower than in substance use disorder treatment. Add-on transactions in the sub-sector were up 19% in 2025.

MedTech and devices remains a core European PE focus. ARCHIMED holds the deepest European MedTech portfolio among specialist GPs, covering diagnostics, surgical devices, and connected health tools. The most active GPs by deal count in European MedTech skew toward specialist platforms rather than generalist buyout firms.

Pharma services and CDMOs (contract development and manufacturing organisations) attract consistent deal flow as infrastructure for global drug development pipelines. Cathay Capital and Sagard both hold pharma services exposure across their European portfolios.

Healthcare staffing has seen renewed interest as workforce shortages in nursing and allied health create platform-building opportunities. PE-backed staffing platforms have used the post-pandemic labour tightening to build scale in locum and travel nurse markets across the US and UK.

Tracking Healthcare Private Equity News: The Data Layer

Most sources for healthcare private equity news rely on press releases, legal filings, and trade publications. The underlying deal data (which GP holds which company, at what entry date, and with what outcome) remains largely opaque without a verified database.

GP Intel tracks over 1,000 private equity firms and more than 21,000 portfolio companies, with hand-checked entry and exit records, fund sizes, and sector classifications. Healthcare coverage spans exclusive specialists such as ARCHIMED, cross-sector platforms with dedicated healthcare verticals, and growth equity investors in HealthTech.

For readers whose search intent is "healthcare private equity news today" or "deals in the last two days," the GP Intel directory can be filtered by sector to surface active healthcare funds and recent portfolio additions. Verified exits, including date, deal type, and buyer (for Pro subscribers), are updated weekly.

The methodology page describes how GP Intel sources and verifies portfolio data, fund sizes, and exit records against primary sources: no automated scraping, every entry reviewed by hand. That editorial discipline is what enables these pages to carry sourced deal data rather than generic news commentary.